Sign in
Taking people in United StatesPhase 1

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
110 people, planned
Started
1 Oct 2026
Expected to end
Aug 2030
Type of study
Interventional, 2 groups
Treatments tested
  • [11C]OMAR
Record updated
2 October 2026

Who can take part

Age
25 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • All
  • Normal screening bloodwork
  • Adequate arterial access for placement of an arterial line and blood sampling per study protocol; OUD Participants:
  • Diagnosis of opioid use disorder (OUD) according to DSM-5 criteria
  • Actively seeking treatment for OUD
  • Willingness to initiate opioid agonist therapy (OAT) with buprenorphine; Healthy Controls:
  • Good general physical health
  • No current or past diagnosis of any psychiatric or substance use disorders

Who cannot take part

  • Prior participation in research studies within the past year that would result in cumulative radiation exposure exceeding annual limits
  • Previous enrollment in the main study; Healthy Controls:
  • Any current major medical condition that, in the opinion of the Principal Investigator, poses a risk for PET procedures
  • History of neurological conditions, including stroke or seizure disorders
  • Current or past diagnosis of a serious psychiatric disorder
  • Current diagnosis of any substance use disorder other than nicotine or opioids
  • Current or past diagnosis of any psychiatric disorder
  • Current diagnosis of any substance use disorder (excluding nicotine)
  • All
  • Presence of ferromagnetic metal in the body, pacemaker, or other contraindications to MRI
  • Positive pregnancy test or current lactation
  • Hematocrit values lower than 30; OUD Participants
  • Use of any substances within the past 30 days
  • Current use of SSRIs or benzodiazepines or use within the past 30 days
  • Use of any substances within the past 30 days

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Opioid use disorder or oat

This trial is currently available in United States.

  • Connecticut Mental Health Center, Clinical Neuroscience Research UnitNew Haven, United StatesContact: Abigail DeweyTaking people

About the trial

What the trial wants to find out

The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls.

The 2 groups in the trial

  • Healthy VolunteersOther group

    Healthy volunteers with no current or past major medical or psychiatric history

    Treatment: [11C]OMAR

  • Opioid Use Disorder in Opioid Agonist Therapy (OAT)Other group

    Patients diagnosed with opioid use disorder during the early phase of opioid agonist therapy

    Treatment: [11C]OMAR

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07800520, who can take part
Record updated
2 October 2026